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Mutations in the MTR gene, which encodes methionine synthase on human chromosome 1p43, result in the
methylcobalamin deficiency G (cblG) disorder, which is characterized by homocystinuria, hyperhomocysteinemia,
and hypomethioninemia. To investigate the molecular basis of the disorder, we have characterized the structure of
the MTR gene, thereby identifying exon-intron boundaries. This enabled amplification of each of the 33 exons of
the gene, from genomic DNA from a panel of 21 patients with cblG. Thirteen novel mutations were identified.
These included five deletions (c.12-13delGC, c.381delA, c.2101delT, c.2669-2670delTG, and c.2796-2800del-
AAGTC) and two nonsense mutations (R585X and E1204X) that would result in synthesis of truncated proteins
that lack portions critical for enzyme function. One mutation was identified that resulted in conversion of A to C
of the invariant A of the 3′ splice site of intron 9. Five missense mutations (A410P, S437Y, S450H, H595P, and
I804T) were identified. The latter mutations, as well as the splice-site mutation, were not detected in a panel of
50 anonymous DNA samples, suggesting that these sequence changes are not polymorphisms present in the general
population. In addition, a previously described missense mutation, P1173L, was detected in 16 patients in an
expanded panel of 24 patients with cblG. Analysis of haplotypes constructed using sequence polymorphisms iden-
tified within the MTR gene demonstrated that this mutation, a CrT transition in a CpG island, has occurred on
at least two separate genetic backgrounds.
Introduction
The methylcobalamin deficiency G (cblG) disorder (MIM
250940) is the result of mutations affecting the MTR
gene, which encodes the cytoplasmic enzyme methio-
nine synthase (EC 2.1.1.13). This enzyme catalyzes the
methylation of homocysteine to generate methionine,
using 5-methyltetrahydrofolate as a methyl-group do-
nor, and requires the presence of an enzyme-bound
cobalamin prosthetic group for activity. The reaction
proceeds by transfer of the methyl group from 5-meth-
yltetrahydrofolate to the enzyme-bound cobalamin to
formmethylcobalamin and by subsequent transfer of the
methyl group from methylcobalamin to homocysteine
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to form methionine (Matthews 1999; Matthews and
Ludwig 2001). Activity of methionine synthase depends
on the presence of a second protein, methionine syn-
thase reductase, which maintains the methionine syn-
thase–bound cobalamin in its fully reduced active state.
When the cobalamin becomes oxidized, methionine syn-
thase reductase catalyzes its reductive methylation, using
S-adenosylmethionine as a methyl donor to regenerate
methylcobalamin (Olteanu and Banerjee 2001).
Methionine synthase activity is important for main-
taining adequate levels of methionine and for preventing
accumulation of homocysteine. Increased blood levels
of homocysteine have been associated with increased
likelihood of developing cardiovascular disease, birth
defects, and Down syndrome, and they may affect the
development of some types of cancer (Carmel and Ja-
cobsen 2001). Methionine synthase is also critical in the
methylation cycle, which maintains the cellular level of
the methionine derivative S-adenosylmethionine. This
molecule acts as methyl group donor in a wide variety
of cellular processes, including DNA and RNA meth-
ylation and neurotransmitter synthesis. Becausemethio-
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nine synthase is the only enzyme in mammalian cells
that uses 5-methyltetrahydrofolate, deficient activity
also results in the trapping of cellular folate as 5-methyl-
tetrahydrofolate, which becomes unavailable for other
folate-dependent reactions involved in purine and py-
rimidine biosynthesis and other single-carbon–transfer
reactions.
Inborn errors of metabolism resulting in functional de-
ficiency of methionine synthase are characterized by ho-
mocystinuria, hyperhomocysteinemia, and hypomethio-
ninemia. Patients have typically presented during the first
2 years of life with megaloblastic anemia and develop-
mental delay, but patients who presented as adults have
been reported (Rosenblatt and Fenton 2001). Comple-
mentation analysis demonstrated the existence of two
forms of the disorder—cblG and a second form that
is designated “methylcobalamin deficiency cblE type”
(cblE)—that presumably result from mutations at sep-
arate loci (Watkins and Rosenblatt 1989). Cloning of
the MTR gene (GDB accession number 119440) on
chromosome 1q43 (Leclerc et al. 1996; Li et al. 1996;
Chen et al. 1997) led to the demonstration that mu-
tations in this gene are the cause of the cblG disorder
(Gulati et al. 1996; Leclerc et al. 1996). It was subse-
quently shown that the cblE disorder is the result of
mutations affecting the MTRR gene, on chromosome
5p15.2-15.3, that encodes methionine synthase reduc-
tase (Leclerc et al. 1998).
The cDNA for the human gene encoding methionine
synthase was cloned on the basis of homology with the
Escherichia coli gene encoding cobalamin-dependent
methionine synthase, which had been previously iden-
tified. The human gene encodes a protein that is 1,265
amino acids in length. Several mutations in the gene
have been described in patients with cblG (Gulati et al.
1996; Leclerc et al. 1996; Wilson et al. 1998). We report
further characterization of this gene, defining its intronic
and exonic structure. This has permitted sequencing of
the entire coding sequence of methionine synthase from
genomic DNA of a panel of patients with the cblG dis-
order. A panel of 18 patients with cblG was investigated
by sequence analysis, and an expanded panel of 24 pa-
tients was investigated using restriction-endonuclease
analysis. To date, 28 patients with the cblG disorder
have been identified (Suormala et al. 2001; D.S.R., un-
published data). Thus, this panel of patients with cblG
represents a majority of all recognized patients with this
disorder.
Patients and Methods
Patients
DNA was extracted and sequenced from a panel of
18 fibroblast lines derived from patients with cblG.
DNA from an additional six patients with cblG was
tested for identified mutations, using restriction endo-
nuclease–based assays, as described below. All cell lines
were characterized by decreased functional activity of
methionine synthase and decreased synthesis of meth-
ylcobalamin in intact cells, in the presence of normal
functional activity of a second cobalamin-dependent en-
zyme, methylmalonyl-CoA mutase, and normal synthe-
sis of its adenosylcobalamin coenzyme. The diagnosis of
cblG was in all cases confirmed by somatic cell comple-
mentation analysis. These studies were approved by the
research ethics board of the Royal Victoria Hospital.
Genomic Organization of the Coding Region of the
Human Methionine Synthase Gene
Some of the cDNA clones used for the original se-
quencing of the human methionine synthase cDNA
(Chen et al. 1997) contained intronic sequences. Addi-
tional exon-intron junctions were determined by PCR,
using primers based on the cDNA sequence. PCR prod-
ucts that were larger than the expected size of the cDNA
sequence were assumed to contain intronic sequences
and were sequenced across the junctions. Additional in-
tronic junctions were identified by genomic sequencing
of putative exons. Intron sizes were determined by se-
quencing through the region or by PCR using flanking
primers.
Sequencing of the MTR Gene
Sequencing was performed using genomic DNA
from 18 cblG cell lines. Six additional cell lines
(WG1655, WG1670, WG1671, WG2867, WG2918,
and WG2989) were tested for presence of mutations
detected by sequencing of the other cell lines, using
the restriction endonuclease–based tests described be-
low, but were not sequenced themselves.
Each of the 33 exons of the MTR gene was amplified
separately, using PCR primers within the flanking in-
tronic sequences, such that the entire exon (as well as
exon-intron boundaries) could be sequenced. Primers
were designed using the Primer 3.0 software available
on the Whitehead Institute/MIT Center for Genome Re-
search server. The sequences of the PCR primers used
are shown in table 1. The annealing temperature for all
primer pairs was 60C. PCR was performed in a total
volume of 50 ml containing 1.25 U AmpliTaqGold poly-
merase (Perkin-Elmer Cetus) in the buffer provided by
the manufacturer, 2.5 mM MgCl2, 0.2 mM dNTPs,
primers at a final concentration of 0.5 mM, and 100 ng
of template genomic DNA. PCR products were purified
with BioMag DNA Sep magnetic beads (PerSeptive Bio-
systems). Sequencing reactions were performed using the
BigDye Primer Cycle Sequencing Ready Reactions-
21M13 kit (PE Applied Biosystems), and products were
analyzed on ABI 377 automated DNA sequencers (PE
Applied Biosystems). Gel files were processed using Se-
Table 1
PCR Primers Used in Sequencing
Exon Sense Antisense
Product Size
(bp)
1 5′-TGTAAAACGACGGCCAGTGTACCCGGGAAGAAAGCAC-3′ 5′-GTGGAGCAAAACACGTAGCC-3′ 457
2 5′-AAGCTCCTCCCTCACACATC-3′ 5′-TGTAAAACGACGGCCAGTTTTATTCTCCGGAGCACTCG-3′ 384
3 5′-TGTAAAACGACGGCCAGTATGTTTATTTTGGGGGCACA-3′ 5′-GCAAACGCTCGTAAGCATCT-3′ 202
4 5′-TGTAAAACGACGGCCAGTCTCATGGTTTGGGAGGAGAA-3′ 5′-AGGACCACAGAGTTGGCATC-3′ 513
5 5′-TGTAAAACGACGGCCAGTATTGGCTATTCATTCACGAC-3′ 5′-GAGTACTTCCCCAAGATCAA-3′ 209
6 5′-TGTAAAACGACGGCCAGTATCCCTAGGCCATTCAGAGG-3′ 5′-TACCCCAGCCTTGTCTGTTT-3′ 207
7 5′-TGTAAAACGACGGCCAGTGTGCTGGGGTTGTGCCTTAT-3′ 5′-AACAGTTGCCTTCCATCAGC-3′ 452
8 5′-TGTAAAACGACGGCCAGTTCTGTTTCTGTGGCTTCCTG-3′ 5′-GCAGCGATCTTCTGAAACCT-3′ 483
9 5′-TTAAGGAGTCCACCCACAGG-3′ 5′-TGTAAAACGACGGCCAGTGAAACACTGCACCCAGACAC-3′ 490
10 5′-GGGGGTGTGGTATCTCTTTG-3′ 5′-TGTAAAACGACGGCCAGTTGGGATTTCTTCAGGGAAAA-3′ 432
11 5′-TCCTATGTCTAGGGCATGTGAT-3′ 5′-TGTAAAACGACGGCCAGTCAGCCCACATTCTGAAACAG-3′ 388
12 5′-TGTAAAACGACGGCCAGTAAAGGCATGATTGTTGCTG-3′ 5′-TACCTGGGCAAATCACCTG-3′ 479
13 5′-TTGTAACAAATAGCCTTTACTGCAT-3′ 5′-TGTAAAACGACGGCCAGTCTGCAAACACACATTACCA-3′ 451
14 5′-AGGGAGTCTGGCGAGGTAGT-3′ 5′-TGTAAAACGACGGCCAGTCAACTGGCACGGTTAAATGA-3′ 338
15 5′-TGTAAAACGACGGCCAGTTCCAAGTATTTTGGGCTTAAAGA-3′ 5′-ACGTTGGCACAATGACAAAA-3′ 597
16 5′-TGTAAAACGACGGCCAGTGGAAGCTGCTTGGCATTTAG-3′ 5′-GCGAGTTCATCAGGCTCTGT-3′ 601
17 5′-TGTAAAACGACGGCCAGTTGTAATACGGCAAGCTTTGG-3′ 5′-TAGGTGTGGCTCTATCCCAAT-3′ 425
18 5′-TGTAAAACGACGGCCAGTCTGTGGCTGCTTTTATGCTG-3′ 5′-CACCACCATCTCTGCAACTC-3′ 453
19 5′-TGTAAAACGACGGCCAGTCAGTCTACTAGGGGCTGGAAAA-3′ 5′-CTCCCCAGGTTGAGAATCAG-3′ 344
20 5′-TGAGGAAACTGAGGCTTATTGA-3′ 5′-TGTAAAACGACGGCCAGTACTCTGAACGCGGATTCTTG-3′ 520
21 5′-TGTAAAACGACGGCCAGTGCTGTCCTGAAGTCAAAGCA-3′ 5′-AAGGGAGAGATGTGGGATCA-3′ 363
22 5′-TGTAAAACGACGGCCAGTACTGTTTGGGCTTCGTTTTC-3′ 5′-TCAAAAACACAGCAAGCAAAA-3′ 400
23 5′-TTAGCATAGTGCCTGGCGTA-3′ 5′-TGTAAAACGACGGCCAGTAAATGGCAATGAAAGCAACC-3′ 432
24 5′-TGTAAAACGACGGCCAGTGGGCAACAGAATGAGACTCC-3′ 5′-GCAAGCCAAAGAAATCCAAG-3′ 542
25 5′-TGTAAAACGACGGCCAGTAATGGCGGTGAACAAGAGTT-3′ 5′-TGCAAGCTTTCCAACACATC-3′ 207
26 5′-TGTAAAACGACGGCCAGTCCAAGCCCACTGAGTTTACC-3′ 5′-GACACTGAAGACCTCTGATTTGAA-3′ 433
27 5′-GGCCATGGGAAGACCAGTTA-3′ 5′-TGTAAAACGACGGCCAGTCACACAACACCTGCTCCATAA-3′ 596
28 5′-ACTCCTACGGGTGACAGGAG-3′ 5′-TGTAAAACGACGGCCAGTATCCAAATCCACTGCTCCTC-3′ 376
29 5′-AAGAAGCATTGTTTGATGGT-3′ 5′-TGTAAAACGACGGCCAGTTGAAGCAGACCCTCATTTAT-3′ 355
30 5′-TGTAAAACGACGGCCAGTTCCAAGTACTGGGGATGTAACAG-3′ 5′-TCAAGGTTTTTCTTTGCCTCA-3′ 5,675
31 5′-TGTAAAACGACGGCCAGTGTGTCCTCATGGTTCTAATTCA-3′ 5′-TACTGAAGAAGGAAGACAGGA-3′ 332
32 5′-TGTAAAACGACGGCCAGTAGACACTGAGTCCATAAGCA-3′ 5′-GCAAGCCACATATAATGAA-3′ 189
33 5′-GAAACTTCTATTCCAAAAGTC-3′ 5′-TGTAAAACGACGGCCAGTTTGTTGTTGTTATTTTTAAGG-3′ 230
NOTE.—Primers are those used for sequencing of the methionine synthase gene from genomic DNA. The M13 tail included in one of the PCR primers is indicated by underlining.
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quence Analysis software (PE Applied Biosystems) and
then were assembled and analyzed using Autoassembler
2.0 (PE Applied Biosystems).
Restriction Endonuclease Analysis
MaeIII was purchased from Boehringer Mannheim;
the remaining restriction endonucleases (Bsp1286I,BsrI,
BstNI, BstUI, DdeI, HinfI, MspI, and NspI) were pur-
chased from New England Biolabs. When a sequence
change detected on sequence analysis resulted in the cre-
ation or destruction of a restriction site, DNA was am-
plified by the same primers used for sequencing, and the
PCR product was digested with the appropriate restric-
tion endonuclease, using the buffer and reaction con-
ditions specified by themanufacturer. Digestion products
were separated by electrophoresis on 2% agarose gels
or on 10% polyacrylamide (29:1 acrylamide:bis-ac-
rylamide) gels, depending on the sizes of the products
to be separated. Two sequence changes that did not re-
sult in the creation or destruction of a restriction site
were confirmed by use of primers that resulted in the
creation of artificial restriction sites in PCR products.
For the c.1310CrA sequence change in exon 14, alter-
native PCR primers were designed (sense: 5′-CCAGATT-
TTGCAACTTAATTGATT-3′; antisense: 5′-CCCTGTT-
TTCGAT GTTGAGA-3′) that resulted in the creation of
aHinfI restriction site in wild-type DNA that was absent
in DNA containing the sequence change. For the c.2669-
2670delTG sequence change in exon 25, alternative PCR
primers were designed (sense: 5′-CTGGACGCGTCCA-
AGACT-3′; antisense: 5′-GACATGGTCACCTGGAC-
CTC-3′) that resulted in the creation of a BsrI restriction
site when the mutant sequence was present, a sequence
that was absent when wild-type DNA was amplified.
For a third deletion that did not result in the creation
or destruction of a restriction site (c.2796-2800del-
AAGTC), the amplicon was incubated with NspI to
generate smaller DNA fragments, and mutations were
recognized on the basis of heteroduplex formation on
polyacrylamide gel electrophoresis.
Results
Organization of the Human MTR Gene
The coding region of the human methionine synthase
gene is composed of 33 exons and 32 introns. The nu-
cleotide sequences at the splice junctions and the ap-
proximate size of each intron are summarized in table
2. All the introns, except for intron 21, follow the GT-
AG rule. The start ATG (1) is in exon 1.
All 33 exons of the methionine synthase gene were
sequenced in a panel of 18 cblG fibroblast lines. Genomic
DNA from six additional patients with cblGwas analyzed
for the presence ofmutations detected in the original panel
using restriction endonuclease–based techniques de-
scribed below. This panel included cell lines that had been
investigated previously (WG1655, WG1670, WG1671,
WG1765, WG1892, and WG2290) (Gulati et al. 1996;
Leclerc et al. 1996; Wilson et al. 1998). Thirteen novel
mutations were identified. Furthermore, one previously
identified mutation (c.3518CrT [P1173L]) was identified
in several additional cell lines. Allmutations inmethionine
synthase that have been identified to date are shown in
figure 1. All detected mutations were present in the het-
erozygous state (table 3).
The Recurrent c.3518CrT Mutation (P1173L)
The c3518CrTmutation, which results in replacement
of proline by leucine at position 1173 of the amino acid
sequence, had been previously identified by Gulati et al.
(1996). It was identified by sequence analysis in 14 of the
18 cblG lines in the panel of the present study (table 3),
including WG1892, the cell line in which it was originally
identified. The c3518CrT mutation results in loss of an
MspI site (Gulati et al. 1996). Restriction-endonuclease
analysis confirmed the presence of the sequence change
in DNA from the 14 cell lines; in addition, the sequence
change was detected in DNA from two additional cblG
cell lines that had not undergone sequencing. The
c3518CrTmutationwas thus detected in 16 of 24 patient
cell lines in total. The sequence change was not detected
in a panel of 50 anonymous control DNA samples tested
by restriction-endonuclease digestion.
Novel Methionine Synthase Mutations
c.12-13delGC.—Sequence analysis of DNA from
WG1765 demonstrated the presence of a 2-bp deletion
at position 12 in exon 1, resulting in a frame shift, with
the loss of normal amino acid sequence starting at codon
5 and creation of a stop codon at position 20. This
sequence change resulted in loss of a BstUI site. Restric-
tion analysis with BstUI confirmed the presence of c.12-
13delGC in WG1765; this change was not detected in
DNA from any other patient with cblG.
c.381delA.—Sequence analysis indicated a single–
base-pair deletion in exon 4 of DNA from WG2829.
This resulted in a frame shift, with altered amino acid
sequence, beginning at codon 128, and the creation of
a stop signal at codon 132.
IVS92ArC.—Sequence analysis of exon 10 from
WG1308 showed a sequence change resulting in alter-
ation of the invariant A at the splice site at the 3′ end
of intron 9. This mutation is expected to result in de-
letion of exon 10 from the methionine synthase tran-
script. This sequence change resulted in the creation of
an MspI restriction site. Restriction-endonuclease anal-
ysis confirmed the sequence change in WG1308. The
sequence change was not detected in DNA from any
other patient with cblG, nor was it detected in a panel
of 50 anonymous control DNA samples.
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Table 2
Intron-Exon Junctions in the Coding Region of the Human MTR Gene
Exon Position 5′ Splice Donor Intron
Size
(kb) 3′ Splice Acceptor
1 394 to 34 TCGCAACCCGgtaacgctgc 1 4.0 ttctttaaagAAGGTCTGAA
2 35–249 AATCCATAAGgtaaagtatt 2 2.4 cttgttgcagGAATACTTGC
3 250–339 TGAACACTTGgtaagaattc 3 2.4 gatacgttagGCCTACCGGA
4 340–409 TGAACACTTGgtaagaattc 4 1.7 tttcccaaagGAATTAAGAG
5 410–502 AGGAACATCAgtgagtattt 5 2.0 ttttttgcagCATTTGATGA
6 503–609 CAATGCCAAGgtgagttaag 6 2.7 tccctgacagGTAGCCTTGT
7 610–669 GCCTATCTTTgtaagttcta 7 .7 gtcaattcagATTTCAGGGA
8 670–764 AACCACTCTGgtgagtgatc 8 ∼3.5 gtttttctagCATTGGATTA
9 765–865 AACCACTCTGgtgagtgatc 9 1.1 ctttactcagGTCTTCCCAA
10 866–927 GCACCTAAAGgtcaggggtc 10 1.5 ctaaatgcagGATTTTGCTA
11 928–995 ATCATATCAGgtcaggggtc 11 2.2 ttcaactcagGGAAATTGCT
12 996–1075 TTACTGTCTGgtgagtcata 12 2.5 tccttttaagGTCTAGAGCC
13 1076–1188 AACTATGAAGgtgagtggtt 13 3.0 cttccttcagGAAGCCTTGT
14 1189–1329 CATCGCAAAGgttatacaaa 14 2.5 ctgatctcagGTACCTTTGT
15 1330–1515 AGAAGGACAGgtgagtggtt 15 ND ttttccctagGCAACAGAAA
16 1516–1695 AGTCATTAAAgtaagtgtag 16 2.0 tttttgccagGAAACATTAC
17 1696–1812 TGCAATCAAGgtatggtaga 17 .3 ttgcccttagTCTGGCATGG
18 1813–1953 TTATGCCCAGgtagagagac 18 4.5 ttcaattcagACTCAAGGCA
19 1954–2043 CCTTGTGAAGgtaagttaca 19 1.3 tcttttttagGGCATTGAAA
20 2044–2196 TCTACCTCAGgttagcaaaa 20 .9 tttttctcagGTTATAAAGT
21 2197–2304 AGAAGAAGAGgcaagtcatt 21 1.0 tcctttccagGACCCTTACC
22 2305–2405 ATAATTTCCGgtaagttagg 22 ∼3.0 tgtgcctcagAGTTATTGAT
23 2406–2473 CACAAAGCAGgtactgtgca 23 .9 aaaaaaatagATATAATTGG
24 2474–2594 CCACTTCAAAgtaagttata 24 6.0 ttctttttagAACCCACACA
25 2595–2676 TGTGGTGGTGgtaagtgggt 25 ND gcattttcagTGTTCCCAGC
26 2677–2775 GTCTCTCAAGgtaagtggta 26 2.5 tttttaacagGAGAGGAGAT
27 2776–2851 CCTCACCCAGgtctgtttgg 27 1.0 tctcctgtagTGAAGCCCAC
28 2852–3007 AAAACAGTAGgttagtgcag 28 1.8 tttctaatagGTGGAGAGGC
29 3008–3204 AAGGCAACAGgtatggaagg 29 2.5 tggttttaagGCTGAGAAGG
30 3205–3405 GCTGGCAGAGgtaaggcaga 30 .8 gggtcccaagGCCTTTGCAG
31 3406–3598 CAGTCTACAGgtaggaagcc 31 1.4 ctccctctagGCATTAGGTT
32 3599–3711 CAAGGATCAGgtaagctagc 32 .5 tcctttgcagGTTGAGGATT
33 3712–
NOTE.—Nucleotides are numbered from the translation start site. Uppercase letters refer to coding
sequence and lowercase letters indicate intronic sequences; ND p not determined.
c.1228GrC (A410P).—This sequence change, de-
tected in DNA from WG2009, resulted in conversion
of alanine to proline at amino acid 410 of the methio-
nine synthase protein. The sequence change resulted
in the creation of a Bsp1286I restriction site. Restric-
tion-endonuclease analysis confirmed that the se-
quence change was present in DNA from WG2009
but not in DNA from any other patients. The sequence
change was not detected in a panel of 50 anonymous
control DNA samples.
c.1310CrA (S437Y).—This sequence change, de-
tected in WG2306, resulted in replacement of serine
by tyrosine at amino acid 437 of the methionine syn-
thase protein. No restriction site was created or de-
stroyed by this sequence change. Alternative PCR
primers were designed that resulted in the creation of
a HinfI restriction site in wild-type DNA that was
absent in DNA containing the sequence change. Re-
striction-endonuclease analysis using these primers
demonstrated that the sequence change was present
in DNA from WG2306 but not from any other patient
DNA. The sequence change was not detected in a
panel of 50 anonymous control DNA samples.
c.1348-1349TCrCA (S450H).—This sequence change
was observed in DNA from two unrelated patients with
cblG, WG1352 and WG2725, and caused conversion of
serine to histidine at amino acid 450 of the methionine
synthase protein. This sequence change resulted in loss
of aHinfI site in exon 15. Restriction analysis confirmed
that the sequence change was present in DNA from
WG1352 and WG2725 but not in DNA from other pa-
tients. The sequence change was not detected in a panel
of 50 anonymous control DNA samples.
c.1753CrT (R585X).—This sequence change in exon
17 of the MTR gene was detected in DNA from
WG1975 and resulted in the creation of a stop codon
at position 585 of the cDNA sequence. This sequence
change resulted in the creation of a DdeI site. Restric-
tion-endonuclease analysis confirmed the presence of
c1753CrT in DNA fromWG1975; the sequence change
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Figure 1 Identified mutations in human methionine synthase. The exon structure of the methionine synthase gene and the locations of
the mutations identified in the present study and in previous studies are shown. Mutations identified for the first time in the present publication
are shown in bold. The regions of the gene encoding the four domains of the methionine synthase enzyme are also shown.
was not detected in DNA from other patients with cblG,
nor was it detected in a panel of 50 anonymous control
DNA samples.
c1784ArC (H595P).—This sequence change, detected
in exon 17 of DNA from WG1386, resulted in replace-
ment of a histidine residue by proline at amino acid
position 595 of the methionine synthase protein. This
sequence change resulted in the creation of a BstNI re-
striction site in the patient DNA. Restriction-endonu-
clease analysis confirmed the existence of the sequence
change in WG1386 DNA; the sequence change was not
present in DNA from other patients with cblG and was
not detected in a panel of 50 anonymous control DNA
samples.
c.2101delT.—This single–base-pair deletion, detected
in DNA from WG1408, resulted in a frame shift that
involved the loss of normal amino acid sequence (start-
ing at position 701 of the methionine synthase protein)
and the creation of a stop codon at position 707.
c.2411TrC (I804T).—This sequence change resulted
in conversion of isoleucine to threonine at amino acid
804 of the methionine synthase protein in WG1505.
This sequence change resulted in the creation of aMaeIII
restriction site in the patient DNA. Restriction-endo-
nuclease analysis confirmed the existence of the sequence
change in WG1505. The sequence change was not pres-
ent in DNA samples from other patients with cblG and
was not detected in a panel of 50 control DNA samples.
c.2669-2670delTG.—This 2-bp deletion was detected
by sequence analysis in DNA from WG1321. It resulted
in a frame shift, starting at codon 890, and in the cre-
ation of a stop codon at position 898. Alternate PCR
primers were designed that resulted in the creation of
an artificial BsrI site in DNA containing the deletion;
this site was absent in wild-type DNA. Analysis con-
firmed that the mutation was present in WG1321 but
was not present in any other patient in the panel.
c.2796-2800delAAGTC.—A 5-bp deletion was de-
tected on sequence analysis of DNA fromWG2507. This
resulted in a frame shift, beginning at codon 935, and
in the creation of a stop codon at position 945. This
mutation did not result in the creation or destruction of
a restriction site. The amplicon (613 bp) was digested
with NspI, yielding fragments of 268, 205, and 140 bp
for wild-type DNA. The 5-bp deletion affected the 205-
bp fragment, resulting in heteroduplex formation in the
heterozygous individual. Heteroduplex formation oc-
curred in digested DNA fromWG2507 and not in DNA
from any other patient with cblG.
c.3613GrT (E1204X).—This sequence change was de-
tected on sequence analysis of exon 32 of DNA from
WG2292 and resulted in the creation of a stop codon
at position 1204 of the methionine synthase protein.
This sequence change resulted in the loss of a HinfI
restriction site. Restriction-endonuclease analysis con-
firmed the presence of the sequence change in WG2292.
The sequence change was not detected in DNA from any
other patient with cblG.
Polymorphisms in the MTR Gene
Sequencing of the MTR gene also demonstrated the
existence of polymorphisms not associated with cblG
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Table 3
Summary of Mutations Found in Patients with cblG
CELL
LINE
PATIENT
CHARACTERISTICS
FIRST MUTATION SECOND MUTATIONSex/Racea Age at Onset
WG2292 F/W 2 wk c.3518CrT (P1173L) c.3613GrT (E1204X)
WG1975 M/W 1 mo c.3518CrT (P1173L) c.1753CrT (R585X)
WG1308 M/W 1.5 mo c.3518CrT (P1173L) IVS92ArC
WG1505 M/W 2 mo c.3518CrT (P1173L) c.2411TrC (I804T)
WG1386 F/W 3 mo c.3518CrT (P1173L) c.1784ArC (H595P)
WG2507 F/W 6 mo c.3518CrT (P1173L) c.2796-2800delAAGTC
WG2306 F/W 7 mo c.3518CrT (P1173L) c.1310CrA (S437Y)
WG1352 F/W 1 year c.3518CrT (P1173L) c.1348-1349TCrCA (S450H)
WG1321 M/W 1.7 years c.3518CrT (P1173L) c.2669-2670delTG
WG1892 M/W 3.5 years c.3518CrT (P1173L)b c.2641-2643delATCb,c
WG1408 F/W 21 years c.3518CrT (P1173L) c.2101delT
WG2009 M/W 38 years c.3518CrT (P1173L) c.1228GrC (A410P)
WG1671 M/B Neonatal IVS3 –166ArGd c.2112-2113delTCd
WG1670 F/B 2 days IVS3 –166ArGd c.2112-2113delTCd
WG1655 M/W 1.7 mo IVS6 GrAd c.3378insAd
WG1223 F/W 5.5 mo c.3518CrT (P1173L)
WG2989 F/W 1 year c.3518CrT (P1173L)
WG2867 M/W 13 years c.3518CrT (P1173L)
WG2724 M/W 31 years c.3518CrT (P1173L)
WG1765 M/W 2.5 mo c.12-13delGC
WG2725 M/W 2.5 mo c.1348-1349TCrCA (S450H)
WG2290 M/W 2.7 mo c.2758CrG (H920D)c
WG2829 F/W 5 mo c.381delA
WG2918 F/B 3 wk
NOTE.—Mutations detected in the methionine synthase gene in patients with cblG are summarized.
Amino acid changes are given in brackets for missense mutations. The recurrent c3518CrT mutation is
underlined. Cell lines WG2867, WG2918, and WG2989 were not sequenced but were tested, by use of
restriction endonuclease–based methods, for the presence of mutations detected in other cell lines. Note
that at least one mutation was detected from 23 of 24 cell lines and that two mutations were identified in
15 cell lines; the single cell line in which no mutation was identified (WG2918) was not sequenced, but
investigated using restriction endonuclease–based tests only. References are given for mutations already
published elsewhere. Note that the precise location of the GrA change within intron 6 of WG1655 has
not been determined.
a F p female; M p male; W p white; B p black.
b Gulati et al. (1996).
c Leclerc et al. (1996).
d Wilson et al. (1998).
disease. Several of these polymorphisms were detected
in multiple cell lines, including both patients and control
individuals. Two of these, c.3492ArC (R1164R) and
c.3576CrT (L1192L), both in exon 31, were seen as
being different from sequences of the MTR gene pub-
lished elsewhere (Leclerc et al. 1996; Chen et al. 1997).
Additional polymorphisms that were observed include
c.2756ArG (D919G) (Leclerc et al. 1996), c.3144ArG
(A1048A) (Tang et al. 2001), and polymorphismswithin
introns 9 (IVS947insA) and 26 (IVS2643GrA). In
addition, each of two sequence changes (IVS3 –6CrT
and c.858CrT [P286P]) that would not be expected to
affect enzyme function was observed in a single cell line.
Haplotype Analysis of Patients with the Recurrent
c.3518CrT Mutation
Using the results of typing for polymorphisms within
theMTR gene, we were able to determine the haplotypes
of the alleles carrying the c.3518CrT mutation in some
patients (fig. 2). These results demonstrated that the mu-
tation had arisen on at least two different backgrounds.
Thus, in WG1308 and WG1975, c.3518CrT was as-
sociated with the G allele at the IVS2643GrA poly-
morphism and with the C allele at the c.3576CrT poly-
morphism in exon 31. In WG2292, c.3518CrT was
associated with the A and the T alleles, respectively, of
these polymorphisms. It was not possible to identify hap-
lotypes associated with the mutation in the remaining
patients.
Genotype-phenotype correlations.—Table 3 summa-
rizes the mutations detected in theMTR gene in the panel
of patients with cblG, together with clinical information
on the patients. In 15 of the 24 patients, two causal
mutations were identified; in 8 patients, a single muta-
tion was identified; and in 1 patient (WG2918, whose
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Figure 2 Haplotypes of patients with the c.3518CrTmutation.
Haplotypes were constructed using the genotypes of patients for the
polymorphisms c.2756ArG (exon 26), IVS2643GrA, c.3144ArG
(exon 29), c.3492Ar C (exon 31) and c.3576CrT (exon 31) within
the methionine synthase gene. Results are shown for patients that were
informative. Note that WG1308 and WG1975 are homozygous for
the G form of the IVS2643GrA polymorphism 5′ to the mutation;
WG2292 is homozygous for the A form. Similarly, WG1308 and
WG1975 are homozygous for the C form of the c.3576CrT poly-
morphism 3′ to the mutation, whereas WG2292 is homozygous for
the T form.
DNA was analyzed by restriction-endonuclease diges-
tion for known mutations but was not sequenced), no
causal mutation was identified. No patient was homo-
zygous for a single mutation. Four mutations were iden-
tified in more than one patient. The shared mutations
in siblings WG1671 and WG1672 (IVS3 –166ArG and
c.2112-2113delTC) have been described elsewhere
(Wilson et al. 1998). S450H was found in two unrelated
patients (WG1352 and WG2725). The P1173L muta-
tion was present in 16 patients. The identification of
several compound heterozygotes with P1173L plus a sec-
ond mutation suggested that it might be possible to es-
timate the effects of the second mutations by comparing
clinical presentations. Mutations that would be expected
to result in production of truncated, inactive proteins
(E1204X, R585X, and c.2796-2800delAAGTC) were
present together with P1173L in three patients with pre-
sentation during the first months of life. However, pa-
tient WG1408—who had P1173L plus c.2101delT,
which would be expected to produce a protein lacking
enzyme activity—did not come to medical attention until
adulthood.
Discussion
In the present study, we report the organization of the
MTR gene encoding methionine synthase. It is a highly
compressed gene of 33 exons and 32 introns that spans
at least 60 kb, with two intron sizes undefined (table 2).
The gene has also been identified in E. coli (Banerjee et
al. 1989) andCaenorhabditis elegans (GenBank accession
number Z46828), and the cDNA has been identified in
the rat (Yamada et al. 1998). The amino acid sequence
is 55% identical with that of the cobalamin-dependent
methionine synthase from E. coli (Li et al. 1996) and is
92% identical to that of the rat (Yamada et al. 1998). A
survey of sequence similarity allows identification of con-
served residues that may be important for enzyme func-
tion. This allows meaningful comparisons to be made
between the enzyme from humans and that from E. coli,
in which the function of the cobalamin-dependentmethio-
nine synthase has been extensively studied. Methionine
synthase from E. coli is a modular enzyme. Domains have
been identified by tryptic digestion of nativeE. colimethi-
onine synthase and by expression of truncated metH
genes. In E. coli, residues 2–353 constitute a domain in-
volved in the binding and activation of homocysteine
(Goulding et al. 1997). Residues 354–649 are believed to
constitute the 5-methyltetrahydrofolate binding (Gould-
ing et al. 1997). Residues 650–896 constitute the cobal-
amin-binding domain of methionine synthase (Banerjee
et al. 1989). Residues 897–1227 make up the activation
domain and contain the binding site for S-adenosylme-
thionine, which is required for reductive methylation of
enzyme-bound cobalamin (Dixon et al. 1996). The crystal
structures of the domains involved in binding of cobal-
amin (Drennan et al. 1994) and of S-adenosylmethionine
(Dixon et al. 1996) have been determined, and amino
acids directly involved in binding have been identified.
The structure of mammalianmethionine synthase appears
similar to that of the bacterial enzyme, and domains and
critical residues can be identified when the bacterial and
mammalian forma have been aligned.
Of the 13 novel sequence changes identified in the
present report, 7 are predicted to result in premature
termination of the amino acid chain. These range from
c.12-13delGC, which would result in total absence of
functional protein, to c.3613GrT, which would result
in loss of the terminal 62 amino acids of the methionine
synthase protein. On the basis of the modular nature
of methionine synthase, the effects of the various mu-
tations on protein function can be predicted. Thus, c.12-
13delGC would result in a protein lacking all four func-
tional domains. c.381delA would result in a protein
lacking most of the homocysteine-binding domain, as
well as all of the 5-methyltetrahydrofolate-binding, co-
balamin-binding, and activation domains. c.1753CrT
would result in loss of part of the 5-methyltetrahydro-
folate-binding domain, as well as all of the cobalamin-
binding domain and the activating domain. c.2101delT
would result in loss of most of the cobalamin-binding
domain and loss of the entire activation domain. The
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three remaining truncating mutations would result in
loss of parts of the activating domain, including residues
known to be critical for binding of S-adenosylmethio-
nine. It has been shown that an intact activation domain
is critical to the function of methionine synthase. Thus,
a fragment of E. coli methionine synthase lacking the
activation domain is initially able to support methyla-
tion of homocysteine, but activity decays with time and
is ultimately lost (Drummond et al. 1993). Although
these are predictions of resulting structure, it is often
the case that mutations that introduce premature stop
codons are associated with instability of the mRNA.
This was found to be the outcome for c.2112delTC and
c.3378insA, which, coupled with mutations involving
intronic inserts, gave fibroblast mRNA nearly unde-
tectable by northern blot analysis (Wilson et al. 1998).
Five missense mutations within the coding sequence of
the MTR gene were identified in the present study. Al-
though these mutations have not been expressed to con-
firm that they disrupt methionine synthase activity, none
were detected in a survey of DNA samples from the con-
trol population. Three of the mutations (A410P, S450H,
and H595P) affect residues that are conserved in methio-
nine synthase from E. coli, C. elegans, and the rat. S437Y
affects a residue conserved in C. elegans and the rat; E.
coli contains glycine at this position. I804T affects a res-
idue conserved in methionine synthase from the rat; the
equivalent residue in E. coli and C. elegans is valine.
Thus, in four of the five missense mutations, the affected
residue is conserved over considerable phylogenetic dis-
tance, suggesting that these sequence changes have a
significant effect on methionine synthase function. The
final mutation, IVS92CrA, was not observed in the
general population and would be expected to result in
deletion of part of the homocysteine-binding domain of
methionine synthase.
One previously identified mutation, P1173L, was
highly prevalent in the patient samples of the pres-
ent study. It was detected in 16 of 24 mutant fibro-
blast lines in the panel, including WG1892, in which
the mutation had been previously identified (Gulati et
al. 1996). This is clearly a disease-causing mutation,
given its prevalence in patients and its absence in control
subjects (consisting of a total of 210 control individuals
analyzed in the present study and the study by Gulati
et al. [1996]). In addition, it results in replacement of
a highly conserved proline residue at position 1173 by
leucine; P1173 lies between two residues, R1172 and
A1174, that interact directly with S-adenosylmethionine
(Dixon et al. 1996).
The high frequency of the P1173L mutation in pa-
tients with cblG raises the question of whether the mu-
tation has arisen more than once during history. The
majority of the members of the patient panel were of
European descent, including all of the patients who car-
ried the P1173L mutation. Analysis of haplotypes in
patients who carried the P1173L mutation (fig. 2) dem-
onstrated that it has arisen on at least two different
backgrounds. The mutation represents a CrT transition
at a CpG island; such sites are known to be prone to
mutation (Templeton et al. 2000). These data suggest
that P1173L is truly a recurrent mutation that has arisen
more than once during human history.
Clinical findings in patients with the cblG disorder
vary widely. The identification—by the present study
and others—of causal mutations in the cblG disorder
means that it is now possible to attempt to correlate
phenotype with genotype in this disorder, although such
a correlation is limited by the fact that both causal mu-
tations have not been found in all patients. Variation
in clinical presentation in patients carrying one copy of
P1173L in combination with a second mutation may
reflect the effect of the second mutation. Patients with
P1173L in combination with a nonsense mutation that
would be expected to result in production of a trun-
cated, inactive protein showed a wide range of age at
onset (table 3). Some patients (WG2292, WG1975, and
WG2507) showed onset of symptoms within the first
months of life. However, WG1408, who had P1173L
plus a deletion resulting in loss of the cobalamin-binding
and activation domains of methionine synthase, came
to medical attention in adulthood. These results suggest
that genetic modifiers and environmental factors may
significantly affect clinical presentation in patients with
cblG.
Elevated blood levels of homocysteine have been as-
sociated with increased risk of cardiovascular disease and
adverse pregnancy outcomes (Ueland et al. 2001).Homo-
cysteine has also been associated with increased likeli-
hood of occurrence of birth defects, such as neural tube
defects and orofacial clefting (Christensen andRosenblatt
1995; Wong et al. 1999) and Down syndrome (James et
al. 1999), and it may affect development of some types
of cancer (Kim 1999). Polymorphisms in genes encoding
methylenetetrahydrofolate reductase and methionine
synthase reductase (enzymes involved in homocysteine
remethylation) have been shown to affect blood levels of
homocysteine and to be associated with altered risk of
cardiovascular disease and birth defects (Rozen 2001).
To date, studies of the c.2576ArG (D919G)MTR poly-
morphism have been inconclusive. The G form appears
to be associated with lowered plasma total homocysteine
(Wang et al. 1999; Chen et al. 2001; Dekau et al. 2001).
However, no consistent effect on risk of developing car-
diovascular disease (Morita et al. 1999; Hyndman et al.
2000; Chen et al. 2001) or birth defects (Christensen et
al. 1999; Shaw et al. 1999) has been documented. Further
study of MTR mutations and polymorphisms such as
those described in the present publication may shed light
152 Am. J. Hum. Genet. 71:143–153, 2002
on the function of methionine synthase that will be im-
portant beyond development of the cblG phenotype.
Acknowledgments
The authors offer thanks to the clinicians who provided
patient samples and clinical information, to Nora Matiaszuk
for complementation analysis, and to Gail Dunbar for growth
of patient fibroblasts. This work was supported by an oper-
ating grant from the Canadian Institutes for Health Research
(CIHR) and by the CIHR Group Grant in Medical Genetics.
The work of B.S. and H.-Y.H. was supported by Public Health
Service grants HL58991 and DK42033 from the United States
Department of Health and Human Services. This is a publi-
cation of the Hess B. and Diane Finestone Laboratory in the
Memory of Jacob and Jenny Finestone.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank (for C. ele-
gans methionine synthase gene sequence [accession number
Z46828])
Genome Database, http://gdbwww.gdb.org (for MTR gene
[GDB accession number 119440])
Online Mendelian Inheritance in Man (OMIM),http://www
.ncbi.nlm.nih.gov/Omim/ (for cblG disorder [MIM 250940])
Whitehead Institute/MIT Center for Genome Research,http:
//www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi
(for Primer 3.0 software)
References
Banerjee RV, Johnston NL, Sobeski JK, Datta P, Matthews RG
(1989) Cloning and sequence analysis of the Escherichia coli
metH gene encoding cobalamin-dependent methionine syn-
thase and isolation of a tryptic fragment containing the co-
balamin-binding domain. J Biol Chem 264:13888–13895
Carmel R, Jacobsen DW (eds) (2001) Homocysteine in health
and disease. Cambridge University Press, Cambridge
Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hen-
nekens CH, Hunter DJ (2001) Influence of a methionine
synthase (D919G) polymorphism on plasma homocysteine
and folate levels and relation to risk of myocardial infarc-
tion. Atherosclerosis 154:667–672
Chen LH, Liu M, Hwang H, Chen L, Korenberg J, Shane B
(1997) Human methionine synthase: cDNA cloning, gene
localization and expression. J Biol Chem 272:3628–3634
Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N,
Platt R, Gilfix BM, Rosenblatt DS, Gravel RA, Forbes P,
Rozen R (1999) Genetic polymorphisms in methylenetet-
rahydrofolate reductase and methionine synthase, folate lev-
els in red blood cells, and risk of neural tube defects. Am J
Med Genet 84:151–157
Christensen B, Rosenblatt DS (1995) Effects of folate defi-
ciency on embryonic development. In: Wickramasinghe SN
(ed) Baillie`re’s clinical haematology: megaloblastic anemia.
Baillie`re Tindall, London, pp 617–638
Dekau V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Hum-
phries SE (2001) Gene-environment and gene-gene inter-
action in the determination of plasma homocysteine levels
in healthy middle-aged men. Thromb Haemost 85:67–74
Dixon MM, Huang S, Matthews RG, Ludwig M (1996) The
structure of the C-terminal domain of methionine synthase:
presenting S-adenosylmethionine for reductive methylation
of B12. Structure 4:1263–1275
Drennan CL, Huang S, Drummond JT, Matthews RG, Ludwig
ML (1994) How a protein binds B12: a 3.0 A˚ X-ray structure
of B12-binding domains of methionine synthase. Science 266:
1669–1674
Drummond JT, Huang S, Blumenthal RM, Matthews RG
(1993) Assignment of enzymatic function to specific protein
regions of cobalamin-dependent methionine synthase from
Escherichia coli. Biochemistry 32:9290–9295
Goulding CW, Postigo D, Matthews RG (1997) Cobalamin-
dependent methionine synthase is a modular protein with dis-
tinct regions for binding homocysteine, methyltetrahydrofo-
late, and adenosylmethionine. Biochemistry 36:8082–8091
Gulati S, Baker P, Li YN, Fowler B, Kruger WD, Brody LC,
Banerjee R (1996) Defects in human methionine synthase in
cblG patients. Hum Mol Genet Suppl 5:1859–1865
Hyndman ME, Bridge PJ, Warnica JW, Fick G, Parsons HG
(2000) Effect of heterozygosity for the methionine synthase
2756 ArGmutation on the risk for recurrent cardiovascular
events. Am J Cardiol 86:1144–1146
James SJ, Pogribna M, Pogribny II, Melnyk S, Hine RJ, Gib-
son JB, Yi P, Tafoya DL, Swenson DH, Wilson VL, Gaylor
DW (1999) Abnormal folate metabolism and mutation in
the methylenetetrahydrofolate reductase gene may be ma-
ternal risk factors for Down syndrome. Am J Clin Nutr 70:
495–501
Kim Y-I (1999) Folate and cancer prevention: a new medical
application of folate beyond hyperhomocysteinemia and neu-
ral tube defects. Nutr Rev 57:314–321
Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B,
Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA
(1996) Human methionine synthase: cDNA cloning and
identification of mutations in patients of the cblG comple-
mentation group of folate/cobalamin disorders. Hum Mol
Genet 5:1867–1874
Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins
D, Heng HHQ, Rommens JM, Scherer SW, Rosenblatt DS,
Gravel RA (1998) Cloning and mapping of a cDNA for
methionine synthase reductase, a flavoprotein defective in
patients with homocystinuria. Proc Natl Acad Sci USA 95:
3059–3064
Li YN, Gulati S, Baker PJ, Brody LC, Banerjee R, Kruger WD
(1996) Cloning, mapping and RNA analysis of the human
methionine synthase gene. Hum Mol Genet 5:1851–1858
Matthews RG (1999) Cobalamin-dependent methionine syn-
thase. In: Banerjee R (ed) Chemistry and biochemistry of
B12. John Wiley & Sons, New York, pp 681–706
Matthews RG, Ludwig ML (2001) Microbial modeling of hu-
man disease: homocysteine metabolism. In: Carmel R, Ja-
cobsen DW (eds) Homocysteine in health and disease. Cam-
bridge University Press, Cambridge, pp 100–112
Morita H, Kurihara H, Sugiyama T, Hamada C, Kurihara Y,
Shindo T, Oh-hashi Y, Yazaki Y (1999) Polymorphism of
the methionine synthase gene: association with homocys-
Watkins et al.: P1173L, a Common Mutation in the MTR Gene 153
teine metabolism and late-onset vascular diseases in the Jap-
anese population. Arterioscler Thromb Vasc Biol 19:298–
302
Olteanu H, Banerjee R (2001) Human methionine synthase
reductase, a soluble P-450 reductase-like dual flavoprotein,
is sufficient for NADPH-dependent methionine synthase ac-
tivation. J Biol Chem 276:35558–35563
Rosenblatt D, Fenton WA (2001) Inherited disorders of folate
and cobalamin transport and metabolism. In: Scriver CR,
Beaudet AL, SlyWS, Valle D,Childs B, KinzlerKW,Vogelstein
B (eds) The metabolic and molecular bases of inherited dis-
ease, 8th ed. McGraw-Hill, New York, pp 3897–3933
Rozen R (2001) Polymorphisms of folate and cobalamin me-
tabolism. In: Carmel R, Jacobsen DW (eds) Homocysteine
in health and disease. University of Cambridge Press, Cam-
bridge, pp 259–269
Shaw GM, Todoroff K, Finnell RH, Lammer EJ, Leclerc D,
Gravel RA, Rozen R (1999) Infant methionine synthase var-
iants and risk for spina bifida. J Med Genet 36:86–87
Suormala ST, Baumgartner ER, Fowler B (2001) Characteri-
zation of methylmalonic aciduria and/or hyperhomocystei-
nemia: studies in cultured fibroblasts. J Inher Metab Dis 24:
55
Tang B, Li YN, Kruger WD (2000) Defects in methylthioad-
enosine phosphorylase are associated with but not responsible
for methionine-dependent tumor cell growth. Cancer Res 60:
5543–5547
Templeton AR, Clark AG, Weiss KM, Nickerson DA, Boer-
winkle E, Sing CF (2000) Recombinational and mutation-
al hotspots within the human lipoprotein lipase gene. Am J
Hum Genet 66:69–83
Ueland PM, Nygard O, Vollset SE, Refsum H (2001) The Hor-
daland homocysteine studies. Lipids 36:S33–S39
Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G,
Wilcken DEL (1999) Relationship between total plasma
homocysteine, polymorphisms of homocysteine metabolism
related enzymes, risk factors and coronary artery disease in
the Australian hospital-based population. Atherosclerosis
146:133–140
Watkins D, Rosenblatt DS (1989) Functional methionine syn-
thase deficiency cblE and cblG): clinical and biochemical
heterogeneity. Am J Med Genet 34:427–434
Wilson A, Leclerc D, Saberi F, Phillips JA III, Rosenblatt DS,
Gravel RA (1998) Functionally null mutations in patients
with the cblG variant form of methionine synthase defi-
ciency. Am J Hum Genet 63:409–414
Wong WY, Eskes TKAB, Kuijpers-Jagtman A-M, Sprauwen
PHM, Steegers EAP, Thomas CMG, Hamel BCJ, Blom HJ,
Steegers-Theunissen RPM (1999) Non-syndromic orofa-
cial clefts: association with maternal hyperhomocysteine-
mia. Teratology 60:253–257
Yamada K, Tobimatsu T, Toraya T (1998) Cloning, sequenc-
ing, and heterologous expression of rat methionine synthase
cDNA. Biosci Biotechnol Biochem 62:2155–2160
